The product - StablevaX™
StablevaX™ is a patented disruptive technology – a game changer in the world of vaccines.
Stablepharma has so far identified over 90 vaccines suitable to use with the StablevaX™ technology.
StablevaX™ meets the criteria for usage required by the WHO and can be manufactured at the same cost as current products.
The approved liquid vaccines are dried from a solution of the stabilising sugar trehalose into the pores of a special sponge stored in a normal vaccination syringe. The vaccine is now protected, stored in the sponge, and housed inside a standard syringe at the correct dosage, to use simply add water.
Stabilising the vaccine onto a “sponge” allows for it to be placed within the barrel of an ordinary syringe. Our technology allows us to manufacture StablevaX™ as preloaded syringes, filled with the correct individual doses.
Our founder Dr Bruce Roser identified that the process operating in the “Resurrection Plant” that can survive for decades without water and then resurrect itself, could be used to stabilise other products.
By dehydrating vaccines and using the process that nature uses, we can achieve a form of safe ‘suspended animation’ to stabilise most vaccines.
We don’t make or develop vaccines - we take existing WHO approved vaccines, stabilise them, and deliver them in a unique way with our patented process.
Trehalose’s stabilising properties are already used in c. 25 approved pharmaceuticals worldwide. To date we have identified c. 90 vaccines suitable for our process – this is a game changer.
The StablevaX™ product consists of an auto disable syringe containing a vaccine stabilised within a compressible “sponge”
- Water is drawn into syringe prior to injection, this results in the liberation of vaccine from the “sponge” in less than 10 seconds
- Air is removed from the syringe following standard practice
- Vaccine is then administered via compression of the “sponge” by the plunger, we use auto - disabling syringes
The science behind this ground breaking invention has been proven
6 years of R&D work concluded with an independent study conducted by UK’s National Institute for Biological Standards and Control (NIBSC) that confirmed a StablevaX™ version of the Tetanus vaccine produced the same level of antibody response as the existing fresh vaccine produced by leading pharmaceutical companies.
Having achieved this milestone of successful testing in animals, we are now able to move forward to the next milestone of Clinical Trials in humans.